All XRAYs

Study: FDA approves new targeted therapy for advanced pancreatic cancer

A new treatment called Bizengri has been approved by the FDA for patients with advanced or metastatic pancreatic cancer. This treatment targets pancreatic cancer or non-small cell lung cancers that have a rare tumor mutation called an NRG1 fusion. (Posted 7/24/25)

Study: Possible link between BRCA1 and BRCA2 mutations and rare breast implant-associated lymphoma

The causes of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare cancer that develops near implants, are unknown. Results from this study suggest that people with an inherited mutation in BRCA1 or BRCA2 may be at increased risk for BIA-ALCL. However, because very few cases of BIA-ALCL occurred among participants, more research is needed to confirm or refute this finding. (Posted 7/14/2025)

Study: New FDA approval of Itovebi, a drug that may improve treatment for certain advanced or metastatic breast cancers

About one-third of hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancers have a PIK3CA tumor mutation that can increase cancer growth and lead to treatment resistance. A new targeted therapy, Itovebi (inavolisib), improved patient outcomes when combined with standard treatment. This led to the recent FDA approval of the drug. (Posted 7/3/25)

Study: Hereditary pancreatic cancer among people of Hispanic ancestry in Mexico

This study looks at people of Mexican ancestry who have pancreatic cancer to identify mutations linked to hereditary cancer. Knowledge of a hereditary cancer mutation can inform patients and their family members about the need for additional surveillance or different treatment options. Access to genetic testing in Mexico is more limited than in the United States. This study emphasizes the importance of genetic testing for inherited cancer risk in pancreatic cancer patients in Mexico. (posted 6/25/25)

Study: Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer

Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)

Study: Impact of mental healthcare among those with increased pancreatic cancer risk

Pancreatic cancer is often aggressive and diagnosed at a late stage, which can lead to uncertainty and fear. For those at risk due to a genetic mutation or family history, access to surveillance and mental health support is essential to help manage the emotional impact.  (Posted 5/12/25)

Este artículo está disponible en español 

Study: Two immunotherapy drugs are better than one for some metastatic colorectal cancers

Combining two immunotherapy drugs is a more effective treatment for certain metastatic colorectal cancers than using either treatment drug alone. Used together, Opdivo (nivolumab) plus Yervoy (ipilimumab) slowed cancer growth in MSI-High metastatic colorectal cancers, a type of colorectal cancer often found in Lynch syndrome. The FDA approved this combined treatment for MSI-High metastatic colorectal cancer after progression with chemotherapy. (Posted 4/30/25)

Este artículo está disponible en español

Study: Hereditary cancer mutations among people with multiple myeloma

People with multiple myeloma who have inherited gene mutations are more likely to have had another cancer previously and may respond better to certain treatments than people with multiple myeloma who do not have inherited mutations. Individuals with an inherited BRCA1 and BRCA2 mutation may have a slightly increased risk for multiple myeloma, but more research is needed to confirm this. (Posted 4/23/25)

Este artículo está disponible en español 

Update: News from the FDA: Colorectal cancer screening and treatment

This XRAY review is a summary of FDA colorectal cancer (CRC) updates in the last year, including education regarding CRC screening, three treatment drugs targeting different types of CRC and two colorectal screening tests. (Posted 4/16/25)

Este artículo está disponible en español

Update: Ovarian suppression may reduce breast cancer recurrence

Ovarian suppression—blocking estrogen production in the ovaries—can improve breast cancer outcomes in premenopausal women. This review provides information about ovarian suppression and describes who might benefit. (Posted 3/6/25)

Este artículo está disponible en español.